comparemela.com
  1. Home
  2. Live Updates
  3. Yasminh Karimi - Breaking News

Latest Breaking News On - Yasminh karimi - Page 1 : comparemela.com

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

United statesDavida litmanTocilizumab actemraYasminh karimiUniversity of michigan comprehensive cancer centerInternal medicineMedical oncologyHematology clinicMichigan comprehensive cancer

New Horizons for Diffuse Large B-Cell Lymphoma

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

United statesNew yorkEdwardl morganRoy bragadesteManali kamdarYasminh karimiNeyssa lee roy bragadesteJonathanw friedbergWilmot cancer institute in rochesterKennerly temple churchDrug administrationNeyssa leeWilmot cancer instituteColorado anschutz medical campusNew optionMark fesler

Subcutaneous Epcoritamab Elicits Durable Responses in Relapsed/Refractory LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma, with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

United statesTocilizumab actemraYasminh karimiUniversity of michigan comprehensive cancer centerInternal medicineMedical oncologyHematology clinicMichigan comprehensive cancerSubcutaneous epcoritamabComplete remissionsPatients with relapsed or refractory largeb cell lymphomaLong term outcomesPhase 1 2 epcore nhl trial2023 soho annual meeting

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.